ALGS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.9M
-89.7%
27.8M
+881.6%
2.8M
+1574.6%
169.0K
-77.2%
741.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
2.9M
-89.7%
27.8M
+881.6%
2.8M
+1574.6%
169.0K
-77.2%
741.0K
Operating Expenses
24.8M
-16.5%
29.7M
-0.3%
29.8M
+35.4%
22.0M
-24.5%
29.1M
R&D
18.9M
-21.4%
24.1M
+3.0%
23.4M
+37.1%
17.0M
-28.8%
23.9M
SG&A
5.9M
+4.4%
5.6M
-12.3%
6.4M
+29.6%
4.9M
-4.3%
5.2M
Operating Income
-21890000
-1058.2%
-1890000
+93.0%
-26929000
-23.4%
-21814000
+23.1%
-28361000
EBITDA
-21639000
-1223.5%
-1635000
+93.8%
-26583000
-23.3%
-21557000
+23.4%
-28141000
Net Income
-21860000
-1353.5%
-1504000
+93.5%
-23040000
-15.9%
-19881000
+37.0%
-31537000
EPS (Basic)
$-2.09
-1392.9%
$-0.14
+93.7%
$-2.21
-15.7%
$-1.91
+37.2%
$-3.04
EPS (Diluted)
$-2.09
-1392.9%
$-0.14
+93.7%
$-2.21
-12.2%
$-1.97
+35.2%
$-3.04
Shares (Diluted)
10.5M
+0.3%
10.4M
+0.3%
10.4M
+2.9%
10.1M
-2.5%
10.4M
Aligos Therapeutics (ALGS) — Financials